The U.S. Food and Drug Administration has reopened the comment period on a decision to disallow supplements that contain nonesterified phytosterols from making risk-reduction claims about coronary heart disease. The comment period was reopened as four companies petition the FDA to reconsider the rule.

Full Story:

Related Summaries